1. Home
  2. LIXT vs NBY Comparison

LIXT vs NBY Comparison

Compare LIXT & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • NBY
  • Stock Information
  • Founded
  • LIXT 2005
  • NBY 2000
  • Country
  • LIXT United States
  • NBY United States
  • Employees
  • LIXT N/A
  • NBY N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • NBY
  • Sector
  • LIXT Health Care
  • NBY
  • Exchange
  • LIXT Nasdaq
  • NBY Nasdaq
  • Market Cap
  • LIXT 4.1M
  • NBY 3.4M
  • IPO Year
  • LIXT N/A
  • NBY 2007
  • Fundamental
  • Price
  • LIXT $1.33
  • NBY $0.58
  • Analyst Decision
  • LIXT
  • NBY Strong Buy
  • Analyst Count
  • LIXT 0
  • NBY 1
  • Target Price
  • LIXT N/A
  • NBY $0.85
  • AVG Volume (30 Days)
  • LIXT 22.1K
  • NBY 41.7K
  • Earning Date
  • LIXT 05-12-2025
  • NBY 05-15-2025
  • Dividend Yield
  • LIXT N/A
  • NBY N/A
  • EPS Growth
  • LIXT N/A
  • NBY N/A
  • EPS
  • LIXT N/A
  • NBY 0.57
  • Revenue
  • LIXT N/A
  • NBY $9,781,000.00
  • Revenue This Year
  • LIXT N/A
  • NBY $23.91
  • Revenue Next Year
  • LIXT N/A
  • NBY $32.05
  • P/E Ratio
  • LIXT N/A
  • NBY $1.27
  • Revenue Growth
  • LIXT N/A
  • NBY 20.52
  • 52 Week Low
  • LIXT $1.02
  • NBY $0.36
  • 52 Week High
  • LIXT $3.50
  • NBY $3.15
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 50.90
  • NBY 52.01
  • Support Level
  • LIXT $1.16
  • NBY $0.55
  • Resistance Level
  • LIXT $1.49
  • NBY $0.61
  • Average True Range (ATR)
  • LIXT 0.11
  • NBY 0.02
  • MACD
  • LIXT 0.00
  • NBY 0.00
  • Stochastic Oscillator
  • LIXT 51.45
  • NBY 50.00

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

Share on Social Networks: